In an interview to CNBC-TV18, Surajit Pal, Pharma Analyst at Prabhudas Lilladher shared his views and readings on the latest happenings in pharmaceutical space especially on Sun Pharmaceutical Industries and Aurobindo Pharma.
Rathi recommends booking profit in Lupin at current valuations. He has a neutral rating and a ‘hold‘ on the Sun Pharma stock because there are several triggers which can drive the earning surprise positively